Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.

Abstract: The present invention relates to polymer conjugates. More specifically, the present invention relates to polymer conjugates capable of binding to fungi, to compositions comprising these conjugates and to the use of these conjugates for detecting the presence of fungi in a sample such as, for example, a biological sample. The present invention also provides for the use of said polymer conjugates in the treatment of a fungal infection.

Abstract: The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.

Abstract: The invention provides a D-deoxyribose sugar for use in promoting wound healing wherein the sugar is provided in a carrier and wherein the carrier is a biocompatible matrix material or a hydrogel.

Abstract: The present invention relates to hydrogel compositions comprising polymer conjugates capable of selectively binding to fungi, Gram positive bacteria and/or Gram negative bacteria. The hydrogel compositions can be used for detecting the presence of fungi, Gram positive bacteria and/or Gram negative bacteria in a sample.

Abstract: A single photon source comprises a photon emitter (10), an excitation waveguide (30) arranged to direct excitation photons having a first polarisation direction into the photon emitter, and a collection waveguide (42) arranged to collect photons having a second polarisation direction from the photon emitter. The first polarisation direction is coupled to a first exciton state of the photon emitter and the second polarisation direction is non-parallel to the first polarisation direction and is coupled to a second exciton state of the photon emitter, and the first and second exciton states have substantially equal energies.

Abstract: The present invention relates to a scaffold for the treatment of stress urinary incontinence, wherein the scaffold comprises three layers of polyurethane: a first layer and a third layer in which the polyurethane fibres are randomly orientated and a second layer between said first and third layers in which the fibres are aligned longitudinally; methods of making such scaffolds and uses thereof.

Abstract: A passive filter circuit, for simultaneous dual-nuclear magnetic resonance quadrature transmit-receive that is configured to apply to an input a quadrature phase shift of a first polarity at a Larmor frequency of a first nucleus and a quadrature phase difference of a second polarity, that is opposite the first polarity, at the Larmor frequency of a second nucleus

Abstract: The present invention relates to a heterotrophic methods of culturing algae, particularly Galdieria species, to produce the valuable pigment phycocyanin. The methods rely on high oxygen saturation and controlled base dosing to provide improved phycocyanin production. The present invention further relates to algal biomass, compositions comprising said biomass or phycocyanin, uses thereof in various products, and a reactor for culturing the algae.

Abstract: Provided herein are methods for determining the chance of a tumor not responding to an anti-cancer therapy (e.g., a T cell-based immunotherapy) based on the presence, density, number, and/or location of certain three-cell structures as described herein. The three-cell structures may comprise a T cell, an immunosuppressive tumor-associated macrophage, and an immunosuppressive regulatory T cell. Such methods may be useful for identifying patients not likely to respond to T cell-based immunotherapy. Also provided herein are methods for determining the prognosis and/or invasiveness of a tumor. The present disclosure also encompasses methods for treating a tumor, as well as kits for performing the methods disclosed herein.

Abstract: Disclosed herein are novel compounds for treating apicomplexan parasite related disorders, methods for their use; cell line and non-human animal models of the dormant parasite phenotype and methods for their use in identifying new drugs to treat apicomplexan parasite related disorders, and biomarkers to identify disease due to the parasite and its response to treatment.

Abstract: The disclosure provides for methods of predicting disease progression comprising detecting a modification of one or more disease markers in a glial cell or neuronal cell generated from a skin cell of the subject. The disclosed methods include methods of identifying subjects that are responsive to a therapeutic agent and methods of determining effectiveness of a therapeutic agent.

Abstract: Apparatus for determining the electrical conductivity of target cervical tissue using magnetic impedance spectroscopy comprising: an excitation coil for producing a magnetic field which is capable of inducing currents in the target cervical tissue; a gradiometer for detecting perturbations in said magnetic field caused by said induced currents, the gradiometer including screening means for minimising sensitivity to tissues other than the target tissue; processing means for determining an electrical conductivity of said target cervical tissue from said perturbations.

Abstract: A method of non-destructive detection of surface and near surface abnormalities in a metallic product. The method comprises positioning a sample having a surface under a source of an incident radiation. The surface of the sample is then irradiated with the incident radiation from the source. A scattered radiation is detected and a radiation pattern from the detected scattered radiation is produced. Said radiation pattern is then analysed and the output indicative of the scattered radiation from the sample is produced. Said produced output is then compared with a threshold value, the threshold value indicative of a maximum acceptable detected surface abnormality. Finally, the presence of a surface abnormality is identified when the output exceeds the threshold value.

Abstract: The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.

Abstract: An apparatus for determining a force Ftip applied to a tip of an electrical impedance spectroscopy probe includes a load cell, accelerometer, and a processing means. The probe tip has a substantially planar distal end for contacting human or animal tissue. The load cell measures the force Floadcell applied axially along a longitudinal axis when the probe tip is in contact with human or animal tissue. The accelerometer measures a gravity vector Aaxial. The apparatus includes a means for compensating for the mass of the probe tip using the measured force and the gravity vector to produce a calibrated measurement force F applied to the probe tip.

Abstract: The present invention relates generally to the identification and isolation of human otic progenitor cells. More specifically, the present invention relates to a method of using cell markers to identify and isolate human otic progenitor cells from a mixed population of cells, methods of enrichment and production of human otic progenitor cells, and associated kits for use in identification and/or isolation of human otic progenitor cells, wherein the cell markers are selected from SSEA1 (CD15), disialoganglioside GD3, TRA-2-49 (liver/bone/kidney alkaline phosphatase), SSEA4, ganglioside GD2 and CD141.

Abstract: This disclosure concerns transcription cassettes comprising nucleic acid molecules comprising a nucleotide sequence encoding AP-4 subunits; vectors comprising said transcription cassettes; pharmaceutical compositions comprising said vector; and vectors or compositions for use in the treatment of AP-4-Hereditary Spastic Paraplegia.

Abstract: A monocyte, monocyte derived cell or macrophage infected with an oncolytic herpes simplex virus is disclosed together with uses of such infected cells in the treatment of diseases such as cancer.

Abstract: The present disclosure relates to transcription cassettes comprising nucleic acids encoding RuvBL1 and/or RuvBL2 and the use of said vectors in gene therapy for the treatment of neurodegenerative diseases that result from expression of polymorphic repeat expansions of the GGGGCC (SEQ ID NO: 5) hexanucleotide-repeat sequence in the first intron of the C9ORF72 gene; pharmaceutical compositions comprising said vectors and including uses and methods to treat neurodegenerative diseases.